The FDA has approved Livalo, a statin developed by Kowa Research Institute (KRI) and Kowa Pharmaceuticals America, Inc. (KPA). According to a KPA statement, Livalo is a fully synthetic and highly potent statin engineered in Japan, with a unique cyclopropyl group on the base structure that “contributes to a more effective inhibition of the HMG-CoA reductase enzyme to inhibit cholesterol production, and potentially affords greater low-density lipoprotein cholesterol (LDL-C) clearance and red...